Skip to main content

natalizumab

Generic: natalizumab·Brand: Tysabri

natalizumab: 3 clinical trials tracked.

natalizumab evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about natalizumab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (3)

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

NCT05658497Registry updated 2026-08-11·BIIB
Recruiting

Primary endpoint: Number of Major Congenital Malformations (MCMs)

Observational908 targetStarted 2023-10Completion 2032-078 sites · Australia, Germany, Ireland, Spain…Biogen

A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

NCT05618301Registry updated 2025-08-11·Phase 1
Completed

Primary endpoint: Safety and tolerability as assessed by the incidence of dose-limiting toxicities (DLTs)

Interventionalopen10 enrolledStarted 2023-07Completion 2025-061 site · United StatesWashington University School of Medicine

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

NCT05688436Registry updated 2026-06-04·BIIB
Active, not recruiting

Primary endpoint: Number of Major Congenital Malformations (MCMs)

Observational1,178 targetStarted 2021-09Completion 2031-011 site · United StatesBiogen